MedPAC > Our Work > Drugs, Devices, and Tests > MedPAC comment on CMS’s proposed NCD decision memorandum on monoclonal antibodies that target amyloid for the treatment of Alzheimer’s disease
MedPAC comment on CMS’s proposed NCD decision memorandum on monoclonal antibodies that target amyloid for the treatment of Alzheimer’s disease